Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19153941rdf:typepubmed:Citationlld:pubmed
pubmed-article:19153941lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:19153941lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:19153941lifeskim:mentionsumls-concept:C0473169lld:lifeskim
pubmed-article:19153941lifeskim:mentionsumls-concept:C0036341lld:lifeskim
pubmed-article:19153941lifeskim:mentionsumls-concept:C0018896lld:lifeskim
pubmed-article:19153941lifeskim:mentionsumls-concept:C0289313lld:lifeskim
pubmed-article:19153941lifeskim:mentionsumls-concept:C0171023lld:lifeskim
pubmed-article:19153941lifeskim:mentionsumls-concept:C1513158lld:lifeskim
pubmed-article:19153941pubmed:issue1lld:pubmed
pubmed-article:19153941pubmed:dateCreated2009-1-20lld:pubmed
pubmed-article:19153941pubmed:abstractTextExcessive body weight gain (BWG), hyperglycemia and dyslipidemia are important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in olanzapine-treated schizophrenia patients.lld:pubmed
pubmed-article:19153941pubmed:languageenglld:pubmed
pubmed-article:19153941pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19153941pubmed:citationSubsetIMlld:pubmed
pubmed-article:19153941pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19153941pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19153941pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19153941pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19153941pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19153941pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19153941pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19153941pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19153941pubmed:statusMEDLINElld:pubmed
pubmed-article:19153941pubmed:monthJanlld:pubmed
pubmed-article:19153941pubmed:issn0176-3679lld:pubmed
pubmed-article:19153941pubmed:authorpubmed-author:BaptistePPlld:pubmed
pubmed-article:19153941pubmed:authorpubmed-author:BeaulieuSSlld:pubmed
pubmed-article:19153941pubmed:authorpubmed-author:RangelNNlld:pubmed
pubmed-article:19153941pubmed:authorpubmed-author:Araujo de...lld:pubmed
pubmed-article:19153941pubmed:authorpubmed-author:GaleazziTTlld:pubmed
pubmed-article:19153941pubmed:authorpubmed-author:UzcáteguiEElld:pubmed
pubmed-article:19153941pubmed:authorpubmed-author:El FakihYYlld:pubmed
pubmed-article:19153941pubmed:issnTypePrintlld:pubmed
pubmed-article:19153941pubmed:volume42lld:pubmed
pubmed-article:19153941pubmed:ownerNLMlld:pubmed
pubmed-article:19153941pubmed:authorsCompleteYlld:pubmed
pubmed-article:19153941pubmed:pagination14-9lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:meshHeadingpubmed-meshheading:19153941...lld:pubmed
pubmed-article:19153941pubmed:year2009lld:pubmed
pubmed-article:19153941pubmed:articleTitleRosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.lld:pubmed
pubmed-article:19153941pubmed:affiliationDepartment of Physiology, Los Andes University Medical School, Mérida, Venezuela. trinbap@yahoo.comlld:pubmed
pubmed-article:19153941pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19153941pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:19153941pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:19153941pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19153941lld:pubmed